U.S. stock market midday update: Zenas Biopharma plummets 13.12%, with a surge in trading volume attracting market attention

U.S. Stock Market Midday Update Zenas Biopharma, down 13.12%, with increased trading volume and no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry AbbVie up 0.62%, with increased trading volume. Based on recent key news: On January 5, AbbVie announced its participation in the 44th Annual J.P. Morgan Healthcare Conference. This news may boost investor confidence in the company's future development, driving the stock price up. On January 6, market analysis showed that although AbbVie was rated "Moderate Buy," top analysts are more optimistic about five other stocks. This may have a certain impact on investor sentiment. On January 5, global biopharmaceutical M&A activity was active, expected to continue its momentum into 2026. This industry trend may positively impact companies like AbbVie. The biopharmaceutical sector is active, with a focus on rare diseases. Forte Pharma up 3.90%. Based on recent key news: On January 6, Wolfe Research upgraded Vertex Pharmaceuticals from "Market Perform" to "Outperform," setting a target price of $548. This rating upgrade may positively impact the overall biopharmaceutical industry, driving Forte Pharma's stock price up. On January 4, MarketBeat pointed out that although Vertex Pharmaceuticals currently holds a "Moderate Buy" rating among analysts, top analysts believe five other stocks are more worthy of investment. This indicates increased market confidence in the biopharmaceutical industry, which may indirectly benefit Forte Pharma. On January 6, analysts predicted that large biopharmaceutical companies would see annual revenue and earnings growth of 8% over the next three years. This optimistic industry outlook may boost investor confidence in Forte Pharma, driving the stock price up. The biopharmaceutical industry's outlook is optimistic, with significant capital inflow. Arrowhead Pharmaceuticals up 8.46%. Based on recent news: On January 5, Arrowhead Pharmaceuticals announced that its gene-silencing method, when used in conjunction with tirzepatide, can double weight loss effects within four months. This advancement is considered an important breakthrough for gene-silencing therapy in the weight loss treatment field, driving the stock price up. On January 5, Arrowhead Pharmaceuticals announced that its drug Redemplo received approval from Health Canada to lower triglyceride levels in adults with familial chylomicronemia syndrome (FCS). This approval further enhances market confidence in the company's future growth. On January 6, Arrowhead Pharmaceuticals' CEO and Chief Medical Officer reported the sale of the company's common stock. Nevertheless, the market remains optimistic about the company's future prospects, and the stock price continues to rise. The small nucleic acid drug market has broad prospects, attracting significant investment Stocks Ranked Among the Top by Market Capitalization in the Industry Amgen rose by 1.94%. Based on recent news, On January 6, Amgen announced the acquisition of UK cancer drug developer Dark Blue for $840 million, aiming to expand its oncology product line. This move enhances Amgen's research in targeted protein degradation and leukemia treatment, driving up its stock price. Source: Jinshi Data On January 6, Amgen stated that Dark Blue's main candidate drug DBT 3757 demonstrated strong anti-cancer activity in various leukemia models, further boosting market confidence in its future growth. Source: Wall Street Insight On January 6, Amgen plans to integrate Dark Blue into its existing research organization, further strengthening its early cancer detection efforts, which has increased investor optimism about the company's future development. Source: Zhito Finance Recently, there has been frequent M&A activity in the biopharmaceutical industry, with growing market demand for innovative drugs